stoneroad, The shorts will mess with the fair price until a takeout is announced. For a Biotech like AMRN with a $8 billion market cap, that is the norm. Better hope that JT does nothing to indicate he wants to GIA and build his own BP...the shorts would descend on the stock like the Sioux did on LTC George Custer's 7th Calvary Regiment at the Battle of the Little Bighorn...with the long investors feeling like they were scalped or worse. (Custer got the "worse.")
My trust is that JT is more pragmatic than he is egotistical.
Maybe...Maybe not, the writing is on the wall...Vascepa dominates Omega-3 molecule & market. Amarin owns EPA market irregardless results of ongoing trial. US Patent law 101. BB
Market Data 
Markets 
AI
